Dr Reddy’s Sees Tocilizumab Clear Phase I
Indian Firm’s Biosimilar Rival To Actemra/RoActemra Moves Into Phase III Trials
Dr Reddy’s says it is moving its biosimilar tocilizumab candidate into Phase III trials after successfully completing a Phase I study for the proposed rival to Actemra/RoActemra.
